Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.62
TBPH's Cash-to-Debt is ranked lower than
74% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. TBPH: 1.62 )
Ranked among companies with meaningful Cash-to-Debt only.
TBPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.62  Med: No Debt Max: No Debt
Current: 1.62
Equity-to-Asset 0.44
TBPH's Equity-to-Asset is ranked lower than
74% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TBPH: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
TBPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.69  Med: 0.84 Max: 0.89
Current: 0.44
-0.69
0.89
Debt-to-Equity 0.93
TBPH's Debt-to-Equity is ranked lower than
83% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. TBPH: 0.93 )
Ranked among companies with meaningful Debt-to-Equity only.
TBPH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.64  Med: 0.76 Max: 0.93
Current: 0.93
0.64
0.93
Debt-to-EBITDA -1.08
TBPH's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. TBPH: -1.08 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TBPH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.27  Med: -1.27 Max: -1.08
Current: -1.08
-1.27
-1.08
Piotroski F-Score: 3
Altman Z-Score: 1.37
Beneish M-Score: -4.49
WACC vs ROIC
13.96%
-263.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -686.41
TBPH's Operating Margin % is ranked lower than
71% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. TBPH: -686.41 )
Ranked among companies with meaningful Operating Margin % only.
TBPH' s Operating Margin % Range Over the Past 10 Years
Min: -69152.21  Med: -431.8 Max: -7.36
Current: -686.41
-69152.21
-7.36
Net Margin % -742.60
TBPH's Net Margin % is ranked lower than
73% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. TBPH: -742.60 )
Ranked among companies with meaningful Net Margin % only.
TBPH' s Net Margin % Range Over the Past 10 Years
Min: -69152.21  Med: -432.56 Max: -7.36
Current: -742.6
-69152.21
-7.36
ROE % -77.39
TBPH's ROE % is ranked lower than
69% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. TBPH: -77.39 )
Ranked among companies with meaningful ROE % only.
TBPH' s ROE % Range Over the Past 10 Years
Min: -173.81  Med: -68.39 Max: -64.27
Current: -77.39
-173.81
-64.27
ROA % -46.54
TBPH's ROA % is ranked lower than
60% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. TBPH: -46.54 )
Ranked among companies with meaningful ROA % only.
TBPH' s ROA % Range Over the Past 10 Years
Min: -1241.48  Med: -93.88 Max: -40.6
Current: -46.54
-1241.48
-40.6
ROC (Joel Greenblatt) % -2040.75
TBPH's ROC (Joel Greenblatt) % is ranked lower than
71% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. TBPH: -2040.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TBPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3053.02  Med: -1687.58 Max: -1032.75
Current: -2040.75
-3053.02
-1032.75
3-Year Revenue Growth Rate 437.70
TBPH's 3-Year Revenue Growth Rate is ranked higher than
100% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. TBPH: 437.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TBPH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -33  Med: 202.35 Max: 437.7
Current: 437.7
-33
437.7
3-Year EBITDA Growth Rate -6.70
TBPH's 3-Year EBITDA Growth Rate is ranked lower than
61% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. TBPH: -6.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TBPH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.7  Med: 95.2 Max: 197.1
Current: -6.7
-6.7
197.1
3-Year EPS without NRI Growth Rate -4.70
TBPH's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. TBPH: -4.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TBPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.7  Med: 78.2 Max: 161.1
Current: -4.7
-4.7
161.1
GuruFocus has detected 3 Warning Signs with Theravance Biopharma Inc TBPH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TBPH's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TBPH Guru Trades in Q3 2016

Seth Klarman 7,350,991 sh (unchged)
Chuck Royce 118,800 sh (-55.29%)
» More
Q4 2016

TBPH Guru Trades in Q4 2016

Joel Greenblatt 9,571 sh (New)
Steven Cohen 170,700 sh (New)
Seth Klarman 9,273,991 sh (+26.16%)
Chuck Royce 103,300 sh (-13.05%)
» More
Q1 2017

TBPH Guru Trades in Q1 2017

Chuck Royce 103,300 sh (unchged)
Seth Klarman 9,273,991 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 90,700 sh (-46.87%)
» More
Q2 2017

TBPH Guru Trades in Q2 2017

Seth Klarman 9,273,991 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 93,300 sh (-9.68%)
» More
» Details

Insider Trades

Latest Guru Trades with TBPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-03-31 Sold Out $28.28 - $37.06 $ 32.301%0
Seth Klarman 2016-12-31 Add 26.16%0.81%$24.57 - $38.58 $ 32.304%9,273,991
Joel Greenblatt 2016-12-31 New Buy$24.57 - $38.58 $ 32.304%9,571
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SZSE:300009, XMCE:ALM, NAS:IMMU, NYSE:CBM, XKRX:006280, HKSE:01548, NAS:AKCA, OSTO:VITR, SZSE:002653, OCSE:ALK B, LSE:GNS, XPAR:DBV, NAS:ARRY, ROCO:4147, NYSE:EBS, SZSE:300347, NAS:RGEN, TSE:4974, SZSE:002821, XSWX:IDIA » details
Traded in other countries:0TB.Germany,
Headquarter Location:Cayman Islands
Theravance Biopharma Inc is a diversified biopharmaceutical company. It is engaged in discovery, research, development and commercialization of human therapeutics.

Theravance Biopharma is a diversified biotechnology company that creates medicines to treat serious illnesses. The company's research and development are concentrated primarily on four therapeutic areas-infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease. Its commercial infrastructure is focused primarily on the acute care setting. The company uses strategic collaboration with other industry players. Theravance generates the majority of its revenue in the U.S. and Europe, followed by Asia.

Top Ranked Articles about Theravance Biopharma Inc

Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017
Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva
Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference
Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)
Theravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update
Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis

Ratios

vs
industry
vs
history
PB Ratio 7.14
TBPH's PB Ratio is ranked lower than
73% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. TBPH: 7.14 )
Ranked among companies with meaningful PB Ratio only.
TBPH' s PB Ratio Range Over the Past 10 Years
Min: 1.5  Med: 2.85 Max: 9.42
Current: 7.14
1.5
9.42
PS Ratio 49.52
TBPH's PS Ratio is ranked lower than
76% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. TBPH: 49.52 )
Ranked among companies with meaningful PS Ratio only.
TBPH' s PS Ratio Range Over the Past 10 Years
Min: 10.34  Med: 27.45 Max: 262.52
Current: 49.52
10.34
262.52
EV-to-EBIT -7.58
TBPH's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. TBPH: -7.58 )
Ranked among companies with meaningful EV-to-EBIT only.
TBPH' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.9  Med: -2.85 Max: -0.8
Current: -7.58
-9.9
-0.8
EV-to-EBITDA -7.72
TBPH's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. TBPH: -7.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
TBPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.1  Med: -2.9 Max: -0.8
Current: -7.72
-10.1
-0.8
EV-to-Revenue 51.03
TBPH's EV-to-Revenue is ranked lower than
73% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. TBPH: 51.03 )
Ranked among companies with meaningful EV-to-Revenue only.
TBPH' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.3  Med: 23.9 Max: 180.5
Current: 51.03
5.3
180.5
Current Ratio 6.74
TBPH's Current Ratio is ranked higher than
68% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. TBPH: 6.74 )
Ranked among companies with meaningful Current Ratio only.
TBPH' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 6.79 Max: 10.73
Current: 6.74
0.38
10.73
Quick Ratio 6.53
TBPH's Quick Ratio is ranked higher than
68% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. TBPH: 6.53 )
Ranked among companies with meaningful Quick Ratio only.
TBPH' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 6.57 Max: 10.48
Current: 6.53
0.1
10.48
Days Inventory 1.00
TBPH's Days Inventory is ranked higher than
97% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. TBPH: 1.00 )
Ranked among companies with meaningful Days Inventory only.
TBPH' s Days Inventory Range Over the Past 10 Years
Min: 1  Med: 1032.22 Max: 1401.54
Current: 1
1
1401.54
Days Sales Outstanding 15.66
TBPH's Days Sales Outstanding is ranked higher than
86% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. TBPH: 15.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
TBPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.85  Med: 12.84 Max: 321.39
Current: 15.66
4.85
321.39
Days Payable 686.29
TBPH's Days Payable is ranked higher than
97% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. TBPH: 686.29 )
Ranked among companies with meaningful Days Payable only.
TBPH' s Days Payable Range Over the Past 10 Years
Min: 218.57  Med: 892.35 Max: 1473.79
Current: 686.29
218.57
1473.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.80
TBPH's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. TBPH: -17.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TBPH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.8  Med: -12 Max: -6.2
Current: -17.8
-17.8
-6.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 29.10
TBPH's Price-to-Net-Cash is ranked lower than
84% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. TBPH: 29.10 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TBPH' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.32  Med: 5.39 Max: 35.89
Current: 29.1
2.32
35.89
Price-to-Net-Current-Asset-Value 20.97
TBPH's Price-to-Net-Current-Asset-Value is ranked lower than
84% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. TBPH: 20.97 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TBPH' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.83  Med: 3.45 Max: 25.87
Current: 20.97
1.83
25.87
Price-to-Tangible-Book 7.15
TBPH's Price-to-Tangible-Book is ranked lower than
64% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. TBPH: 7.15 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TBPH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.66  Med: 2.67 Max: 8.82
Current: 7.15
1.66
8.82
Price-to-Median-PS-Value 1.80
TBPH's Price-to-Median-PS-Value is ranked lower than
82% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. TBPH: 1.80 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TBPH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.03 Max: 8.88
Current: 1.8
0.33
8.88
Earnings Yield (Greenblatt) % -13.20
TBPH's Earnings Yield (Greenblatt) % is ranked lower than
60% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. TBPH: -13.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TBPH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -123  Med: -35.15 Max: -10.1
Current: -13.2
-123
-10.1

More Statistics

Revenue (TTM) (Mil) $31.36
EPS (TTM) $ -4.67
Beta2.07
Short Percentage of Float42.88%
52-Week Range $23.15 - 43.44
Shares Outstanding (Mil)53.83

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -4.64 -4.10
EPS without NRI ($) -4.64 -4.10
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}